Are we near a future of “designer babies”?
Via NBC News MACH
Are we near a future of “designer babies”?
Via NBC News MACH
News from Veritas and remember Veritas are offering a whole genome sequence as one of the rewards in our AgeMeter campaign at Lifespan.io:
https://www.lifespan.io/campaigns/agemeter-biomarker-scan/#reward_12
“On August 3, sequencing company Veritas Genetics bought one of the most influential: seven-year old Curoverse. Veritas thinks AI will help interpret the genetic risk of certain diseases and scour the ever-growing databases of genomic, medical, and scientific research.”
As one of the most visible 2016 presidential candidates—and now as a leading 2018 contender for Governor in California—Zoltan Istvan has been the “Science Candidate,” traveling around America to discuss the issues of transhumanism and radical longevity that are transforming humanity. Soon the issues of AI, genetic editing, designer babies, bionic organs, automation, and neural prosthetics will challenge and dominate political discourse. America must embrace radical science with bold polices.
“Pay attention to the the trends in exponential technologies, particularly to “the big three.” GNR: Genetics, nanotechnology, and robotics.”
Pay attention to the trends in exponential technologies. particularly to “the big three,” says Jason Silva. Those 3 are GNR: Genetics, Nanotechnology, and Robotics.
https://www.lifespan.io/campaigns/agemeter-biomarker-scan/#reward_13
This is one of the great rewards on offer for supporting AgeMeter, a functional age biomarker system, a project endorsed by Professor Church.
Scientists in Portland, Ore., just succeeded in creating the first genetically modified human embryo in the United States, according to Technology Review. A team led by Shoukhrat Mitalipov of Oregon Health & Science University is reported to “have broken new ground both in the number of embryos experimented upon and by demonstrating that it is possible to safely and efficiently correct defective genes that cause inherited diseases.”
The U.S. team’s results follow two trials—one last year and one in April—by researchers in China who injected genetically modified cells into cancer patients. The research teams used CRISPR, a new gene-editing system derived from bacteria that enables scientists to edit the DNA of living organisms.
The era of human gene editing has begun.